Purpose: This study was designed to investigate the therapeutic effects of oral kallidinogenase medication as an adjuvant therapy in treating patients with diabetic macular edema (DME).
Study design: This was a prospective, open-labeled, randomized study.
Methods: All patients were given posterior sub-Tenon triamcinolone acetonide (STTA) injection and focal laser treatment session for DME. The patients were subdivided into two groups: 1) those treated with oral kallidinogenase for at least 6 months after local treatment (treated group) and 2) those treated without oral kallidinogenase (untreated group). In this study, best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SCT), and chorioretinal blood flow level were measured in 17 patients (19 eyes). Chorioretinal blood flow levels at the disc and macula were measured by laser speckle flowgraphy and evaluated using the mean blur rate (MBR). These data were measured at baseline and at 1, 3, and 6 months after treatment initiation.
Results: BCVA at 6 months after treatment significantly improved in treated group (P<0.05). But the mean CRT after treatment significantly decreased in both groups. There was no significant difference in the mean SCT at baseline between the two groups. The mean SCT after treatment in treated group was significantly thinner than that before treatment (P<0.05). Compared to baseline (100%), MBR at the disc and the macula at 6 months after treatment significantly decreased to 84.8% and 86.2%, respectively, in untreated group (P<0.05), though it remained unchanged at 98.7% and 99.7% in treated group.
Conclusion: Oral kallidinogenase medication is useful as an adjuvant therapy to enhance the therapeutic effect of STTA in DME patients.
Keywords: diabetic macular edema; enhanced depth imaging optical coherence tomography; kallidinogenase; laser speckle flowgraphy.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema.Graefes Arch Clin Exp Ophthalmol. 2018 May;256(5):885-892. doi: 10.1007/s00417-018-3939-3. Epub 2018 Mar 1. Graefes Arch Clin Exp Ophthalmol. 2018. PMID: 29492689
Retinal blood flow levels measured by laser speckle flowgraphy in patients who received intravitreal bevacizumab injection for macular edema secondary to central retinal vein occlusion.Retin Cases Brief Rep. 2014 Winter;8(1):60-6. doi: 10.1097/ICB.0000000000000005. Retin Cases Brief Rep. 2014. PMID: 25372211
Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema.Chin Med J (Engl). 2011 Feb;124(3):352-8. Chin Med J (Engl). 2011. PMID: 21362332 Clinical Trial.
Effects of sub-Tenon's capsule triamcinolone acetonide injection combined with microaneurysm photocoagulation on diabetic macular edema.Int Med Case Rep J. 2015 Dec 7;8:321-6. doi: 10.2147/IMCRJ.S89970. eCollection 2015. Int Med Case Rep J. 2015. PMID: 26675141 Free PMC article.
Practical Lessons from Protocol I for the Management of Diabetic Macular Edema.Dev Ophthalmol. 2017;60:91-108. doi: 10.1159/000459692. Epub 2017 Apr 20. Dev Ophthalmol. 2017. PMID: 28427069 Review.
- Antonetti DA, Barber AJ, Bronson SK, et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes. 2006;55:2401–2411. - PubMed
- Hidayat A, Fine B. Diabetic choroidopathy: light and electron microscopic observations of seven cases. Ophthalmology. 1985;67:512–522. - PubMed
- Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796–1806. - PubMed
- Koga T, Mawatari Y, Inumaru J, Fukushima M, Tanihara H. Trans-Tenon’s retrobulbar triamcinolone acetonide infusion for refractory diabetic macular edema after vitrectomy. Graefes Arch Clin Exp Ophthalmol. 2005;243:1247–1252. - PubMed